Project Grant 2150951
Award Date
4/1/22
Completion Date
3/31/23
Dollars Obligated
$256K
Federal Agency
National Science Foundation
Federal Grant Program
47.084
Assistance Type
Project Grant
Place of Performance
Princeton, NJ 08544, USA
Similar Awards
This Cooperative Agreement award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $999,109 to Cryptyx Bioscience, Inc. to develop a novel drug discovery platform based on high-throughput elicitor screening (HITES) of microbial natural products. The platform aims to unlock the full metabolomic potential of microbes by activating otherwise "silent" biosynthetic pathways, enabling the identification of novel compounds...
This $275,000 Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) will enable Foragr Medicines, Inc. to develop a high-throughput platform for using small molecule drugs to target the messenger RNAs (mRNAs) of previously "undruggable" proteins. The goal is to create an efficient and cost-effective approach for developing new therapeutics for hard-to-treat diseases like neurodegenerative disorders and...
This $303,864 SBIR Phase I project grant awarded by the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) aims to develop a platform for the discovery of disruptive drug candidates. The project seeks to determine the biological laws driving diseases at the molecular network level and translate this understanding into an efficient, scalable algorithm for identifying new drug targets. The overarching goal is to enable the rapid design and...
The U.S. National Science Foundation awarded a $275,000 SBIR Phase I Project Grant to Om Therapeutics Inc. in La Jolla, CA under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program. The project aims to enable the discovery of new medicines at an unprecedented rate by empowering researchers to conduct drug discovery programs through the generation of massive, empirical, and scalable data on small molecule and protein interactions using machine learning. The key innovation is...
This Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) is focused on developing an affordable, portable virus detection platform. The $331,189 project, awarded on April 1, 2025 and running through March 31, 2028, integrates protein engineering and electrochemical biosensor technologies to create a virus detection system that can operate in resource-limited environments. The innovation lies in using stable...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 provides funding to Clue Genetics Inc. for the development of a fungi-focused metabologenomics platform for natural product discovery. The key products and services to be delivered under this 1-year Phase I SBIR project include: Annotating biosynthetic gene clusters (BGCs) from 200 genomes selected from a diverse set of bioactive fungi to uncover new drugs,...
This $273,550 federal Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) supports the development of a novel yeast-based high-throughput screening platform to efficiently generate improved molecular recognition components for use in therapeutic and diagnostic antibodies. The core aim is to leverage breakthroughs in next-generation DNA sequencing, synthetic biology, and computational biology to create a combinatorial...
This Project Grant award from the National Science Foundation (NSF) under its Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $275,000 to Tectaria Bio LLC to engineer cell lines with activated proteasomes for increased biomanufacturing efficiency. The project aims to test the feasibility and application of a novel technology to significantly increase the protein production capabilities of cell lines used in the manufacture of biologics, gene therapies, and vaccines....
This $1 million cooperative agreement from the National Science Foundation's Technology, Innovation, and Partnerships program aims to develop a microbial discovery and biosynthesis platform for targeted protease inhibitors to treat COVID-19. Think Bioscience, Inc. will expand its demonstrated approach using microbial systems to guide the discovery and assembly of protease inhibitors. The company will generate new intellectual property covering the discovery platform and promising small molecules...
This Project Grant award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships program) provides $275,000 to Ubiquitx Inc., a New York-based small business, to develop a programmable, modular therapeutic platform for the direct modification of proteins of interest (POIs) using artificial intelligence, protein engineering, and mRNA therapeutics. The goal is to expand the applications of the company's Chimeric Ligands for Induced Proximity (CLIPS)...